NASDAQ · RCEL
Avita Medical Inc.
$16.71+$0.21 (+1.27%)
Avita Medical Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.12% below the high.
Loading market information…
NASDAQ · RPID · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Rapid Micro Biosystems, Inc.’s quoted price sits in the lower half of its reported 52-week range, 84.03% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Rapid Micro Biosystems, Inc.’s next earnings report is currently expected on Nov 6, 2026, with estimated earnings per share of -$0.20. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Rapid Micro Biosystems, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Rapid Micro Biosystems, Inc. operates as a life sciences technology firm, supplying advanced solutions for identifying microbial impurities in the production processes of pharmaceuticals, medical devices, and personal care goods across North America, Europe, and Asia. Central to their offerings is the Growth Direct platform, a comprehensive system comprising the Growth Direct instrument, specialized disposable components, software for seamless integration with laboratory information management systems (LIMS), and extensive customer validation and support services. This innovative platform is designed to automate and modernize traditional, labor-intensive microbial quality control (MQC) testing workflows, which are critical for diverse therapeutic modalities such as biologics, vaccines, cutting-edge cell and gene therapies, and sterile injectable medications. Beyond their core product, the company also delivers essential services, including system installation, verification, expert technical training, and continuous support. Their technologies are widely applied in vital areas like environmental monitoring, water quality testing, bioburden assessment, and final sterility release evaluations. Established in 2006, the company initially traded as Genomic Profiling Systems, Inc., before rebranding to Rapid Micro Biosystems, Inc. in January 2007, and maintains its headquarters in Lowell, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:09 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 9, 2025 | -$0.26+3.7% vs estimate | $7.21M+4.93% vs estimate |
|---|
| Q4 2024 | Feb 28, 2025 | -$0.220.0% vs estimate | $8.22M+0.22% vs estimate |
|---|
| Q3 2024 | Nov 1, 2024 | -$0.260.0% vs estimate | $7.60M+0.05% vs estimate |
|---|
THE ANALYST VIEW
6 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 2 contributors · Median target $5.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$16.71+$0.21 (+1.27%)
Avita Medical Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.12% below the high.
$4.19+$0.02 (+0.48%)
Owlet, Inc.’s quoted price sits in the lower half of its reported 52-week range, 75.27% below the high.
$2.69+$0.08 (+3.07%)
Apyx Medical Corporation’s quoted price sits in the lower half of its reported 52-week range, 47.05% below the high.
$1.14$0.00 (0.0%)
Vivani Medical, Inc.’s quoted price sits in the lower half of its reported 52-week range, 36.67% below the high.
$0.43+$0.02 (+5.03%)
Lucid Diagnostics Inc.’s quoted price sits in the lower half of its reported 52-week range, 73.48% below the high.
$2.06+$0.03 (+1.48%)
Sera Prognostics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 46.49% below the high.
$5.97+$0.05 (+0.84%)
LENSAR Inc’s quoted price sits in the lower half of its reported 52-week range, 53.86% below the high.
$0.74-$0.01 (-1.28%)
Cognition Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 59.6% below the high.
